智通财经网·2026-02-24 08:46Core Viewpoint - Company has received approval from the National Medical Products Administration for the expanded age range of its meningococcal polysaccharide conjugate vaccine, MCV4, from "3 months to 3 years (47 months) children" to "3 months to 6 years (83 months) children" [1] Group 1 - The product, known as Manhaixin®, is China's first quadrivalent meningococcal conjugate vaccine, which helps bridge the gap in this field between China and developed countries [1] - The approval fills a significant gap in the availability of high-end vaccines in China, providing a better solution for the prevention of meningococcal disease in children aged 6 years and below [1] - Manhaixin® has demonstrated strong market performance and an increasing market share due to its innovative advantages [1]